uniQure hands Chiesi European Glybera marketing rights
This article was originally published in Scrip
After doing all the hard work, gene therapy developer uniQure has signed collaboration agreements with Chiesi Famaceutici for the commercialization of Glybera (alipogene tiparvovec), the first gene therapy to receive regulatory approval in Europe (scripintelligence.com, 2 November 2012), as well as the co-development of a gene therapy for hemophilia B.
You may also be interested in...
UniQure will not seek marketing authorization renewal for Glybera in the EU before it expires in October, but the company does not see the product's commercial failure as a sign that the market won't accept gene therapies or their high price tags.
The UK's main reimbursement bodies made a series of decisions this week that were broadly favorable and largely focused on oncology medicines.
While troubled Valeant was divesting iNova to private equity investors, Novartis announced a pair of oncology-focused deals, out-licensing a brain cancer drug to Midatech and partnering with IBM Watson Health to optimize breast cancer treatment.